SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung

• Main Authors: Alan E Mast, Alisa S Wolberg, David Gailani, Michael R Garvin, Christiane Alvarez, J Izaak Miller, Bruce Aronow, Daniel Jacobson
• Format: Article
• Language: English
• Published: eLife Sciences Publications Ltd 2021-03-01
• Series: eLife
• Subjects: COVID-19; coagulation; fibrinolysis; bronchoalvelolar; SARS-CoV-2
• Online Access: https://elifesciences.org/articles/64330

Extensive fibrin deposition in the lungs and altered levels of circulating blood coagulation proteins in COVID-19 patients imply local derangement of pathways that limit fibrin formation and/or promote its clearance. We examined transcriptional profiles of bronchoalveolar lavage fluid (BALF) samples to identify molecular mechanisms underlying these coagulopathies. mRNA levels for regulators of the kallikrein–kinin (C1-inhibitor), coagulation (thrombomodulin, endothelial protein C receptor), and fibrinolytic (urokinase and urokinase receptor) pathways were significantly reduced in COVID-19 patients. While transcripts for several coagulation proteins were increased, those encoding tissue factor, the protein that initiates coagulation and whose expression is frequently increased in inflammatory disorders, were not increased in BALF from COVID-19 patients. Our analysis implicates enhanced propagation of coagulation and decreased fibrinolysis as drivers of the coagulopathy in the lungs of COVID-19 patients.